Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

277
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
277
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
173
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

281
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
281
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

252
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
252
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

History of Alcohol-Related Cancers and ADH1B/ALDH2 Genotypes in a Large Japanese Cohort of Male Patients With Alcohol Dependence.

Cancer medicine·2026
Same author

Two cases of durvalumab-induced Evans syndrome in biliary tract cancer.

Clinical journal of gastroenterology·2026
Same author

Protective effects of PRELP protein in a mouse model of pulmonary fibrosis.

Respiratory research·2026
Same author

ADH1B-ALDH2 genotype combinations, Age-Related Risk, and Field Cancerization in Head and Neck and Upper GI Cancer Screening in 10,073 Alcohol-Dependent Men.

Carcinogenesis·2026
Same author

Diagnostic performance of magnifying endoscopy with third-generation narrow-band imaging for early gastric cancer: post hoc analysis of a randomized trial (3G detection trial).

Journal of gastroenterology·2026
Same author

Clinical Implications of Nutritional Intake in Patients With Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy and Neoadjuvant Chemotherapy.

Cancer medicine·2026

相关实验视频

Updated: Jun 26, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

新型抗高血糖药与甲福明的关联与喘恶化的减少

Yuya Kimura1, Taisuke Jo2, Norihiko Inoue3

  • 1Department of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Tokyo, Japan; Clinical Research Center, National Hospital Organization Tokyo Hospital, Tokyo, Japan.

The journal of allergy and clinical immunology. In practice
|May 11, 2024
PubMed
概括

葡萄糖携带体-2 抑制剂 (SGLT-2 Is) 显示与甲胺可比的喘控制,与DPP-4 抑制剂和GLP-1 受体激动剂不同. 在喘患者中,SGLT-2 Is可能是治疗2型糖尿病的合适替代品.

关键词:
喘 喘 是一种双基-4 抑制剂的使用.类似葡萄糖类酶1受体激活剂.甲胺是一种甲胺.国家行政数据库.葡萄糖辅运输体-2 抑制剂2 型糖尿病 2 型糖尿病

更多相关视频

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

218

相关实验视频

Last Updated: Jun 26, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

218

科学领域:

  • 内分泌学 在内分泌学.
  • 肺部病理学 肺部病理学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 抗高血糖药物如DPP-4 Is,GLP-1 RAs和SGLT-2 Is可能通过抗炎和代谢途径影响喘控制.
  • 甲胺是2型糖尿病的常见治疗方法,但它对喘恶化的影响是关键的比较点.

研究的目的:

  • 为了比较伴随性喘和2型糖尿病患者在接受新型抗高血糖药物治疗时与甲福明相比,喘恶化的风险.
  • 评估DPP-4 Is,GLP-1 RAs和SGLT-2 Is在这种患者群体中控制喘的有效性.

主要方法:

  • 一项使用日本国家行政数据库 (2014-2022) 的回顾性队列研究.
  • 包括137173名新的DPP-4 Is,GLP-1 RAs,SGLT-2 Is或甲胺使用者,有喘和2型糖尿病史.
  • 倾向性评分权重被用于平衡患者特征;主要结局是需要全身皮质类固醇的第一个恶化.

主要成果:

  • 与甲双相比,DPP-4抑制剂和GLP-1受体激活剂与需要全身皮质类固醇的喘恶化发生率更高有关.
  • 与甲胺相比,糖共运输体-2 抑制剂显示出需要全身皮质类固醇的恶化发生率与甲胺相似.
  • SGLT-2 Is与需要全身皮质类固醇的整体恶化症略有减少.

结论:

  • 与2型糖尿病和喘患者的甲福明相比,DPP-4 Is和GLP-1 RA显示喘控制较差.
  • SGLT-2 提供与甲福尔明可比的喘控制,这表明它们可能是这个患者群体的合适替代品.